دورية أكاديمية
أعرض في EDS

Effects of risk factors for ovarian cancer in women with and without endometriosis.

التفاصيل البيبلوغرافية
العنوان: Effects of risk factors for ovarian cancer in women with and without endometriosis.
المؤلفون: Phung MT; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan., Muthukumar A; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan., Trabert B; Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah; Cancer Control and Population Sciences Program, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah., Webb PM; Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Jordan SJ; University of Queensland, School of Public Health, Brisbane, Queensland, Australia., Terry KL; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Cramer DW; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Titus LJ; Public Health, Muskie School of Public Service, University of Southern Maine, Portland, Maine., Risch HA; Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut., Doherty JA; Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Harris HR; Division of Public Health Sciences, Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington., Goodman MT; Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, California; Department of Biomedical Sciences, Community and Population Health Research Institute, Cedars-Sinai Medical Center, Los Angeles, California., Modugno F; Womens Cancer Research Program, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Moysich KB; Division of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York., Jensen A; Department of Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark., Kjaer SK; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Anton-Culver H; Department of Medicine, University of California, Irvine, Irvine, California., Ziogas A; Department of Medicine, University of California, Irvine, Irvine, California., Berchuck A; Division of Gynecologic Oncology, Duke University School of Medicine, Durham, North Carolina., Khoja L; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan., Wu AH; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California., Pike MC; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Pearce CL; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan., Lee AW; Department of Public Health, California State University, Fullerton, Fullerton, California. Electronic address: alicelee@fullerton.edu.
المصدر: Fertility and sterility [Fertil Steril] 2022 Nov; Vol. 118 (5), pp. 960-969. Date of Electronic Publication: 2022 Sep 29.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: Elsevier for the American Society for Reproductive Medicine Country of Publication: United States NLM ID: 0372772 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-5653 (Electronic) Linking ISSN: 00150282 NLM ISO Abbreviation: Fertil Steril Subsets: MEDLINE
أسماء مطبوعة: Publication: New York. NY : Elsevier for the American Society for Reproductive Medicine
Original Publication: New York, Hoeber.
مواضيع طبية MeSH: Endometriosis*/diagnosis , Endometriosis*/epidemiology , Endometriosis*/chemically induced , Ovarian Neoplasms*/diagnosis , Ovarian Neoplasms*/epidemiology , Ovarian Neoplasms*/etiology, Female ; Humans ; Talc/adverse effects ; Carcinoma, Ovarian Epithelial ; Risk Factors ; Case-Control Studies ; Estrogens
مستخلص: Objective: To evaluate the associations between 10 well-established ovarian cancer risk factors and risk of ovarian cancer among women with vs. without endometriosis.
Design: Pooled analysis of 9 case-control studies in the Ovarian Cancer Association Consortium.
Setting: Population-based.
Patient(s): We included 8,500 women with ovarian cancer, 13,592 control women.
Intervention(s): Ten well-established ovarian cancer risk factors.
Main Outcome Measure(s): Risk of ovarian cancer for women with and without endometriosis.
Result(s): Most risk factor-ovarian cancer associations were similar when comparing women with and without endometriosis, and no interactions were statistically significant. However, body mass index (BMI) 25-<30 kg/m 2 was associated with increased ovarian cancer risk among women with endometriosis (odds ratio [OR] = 1.27, 95% confidence interval [CI] 1.00-1.60), but not associated with the risk among women without endometriosis (OR = 0.97; 95% CI, 0.91-1.05) when compared with BMI 18.5-<25 kg/m 2 ; an increased risk was observed for a BMI ≥30 kg/m 2 , although there was little difference comparing women with endometriosis (OR = 1.21; 95% CI, 0.94-1.57) to women without (OR = 1.13; 95% CI, 1.04-1.22) (P-interaction = .51). Genital talcum powder use and long-term menopausal estrogen-only therapy use showed increased ovarian cancer risk, but risk appeared greater for those with endometriosis vs. those without (genital talcum powder: OR = 1.38; 95% CI, 1.04-1.84 vs. OR = 1.12; 95% CI, 1.01-1.25, respectively; ≥10 years of estrogen-only therapy: OR = 1.88; 95% CI, 1.09-3.24 vs. OR = 1.42; 95% CI, 1.14-1.76, respectively); neither of these interactions were statistically significant (P-interaction = .65 and P-interaction = .96, respectively).
Conclusion(s): The associations between ovarian cancer and most risk factors were similar among women with and without endometriosis. However, there was some suggestion of differences by endometriosis status for BMI, menopausal hormone therapy use, and genital talcum powder use, highlighting the complexity of ovarian cancer etiology.
(Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
References: Cancers (Basel). 2018 Jul 30;10(8):. (PMID: 30061485)
Endocrinology. 2003 Jun;144(6):2195-200. (PMID: 12746274)
Cancer Prev Res (Phila). 2013 Aug;6(8):811-21. (PMID: 23761272)
Int J Cancer. 2008 Jan 1;122(1):170-6. (PMID: 17721999)
J Clin Oncol. 2016 Aug 20;34(24):2888-98. (PMID: 27325851)
J Natl Cancer Inst. 2019 Oct 1;111(10):1097-1103. (PMID: 30753695)
Cytokine Growth Factor Rev. 2018 Dec;44:38-50. (PMID: 30340925)
Cancer Res. 1998 Jan 15;58(2):362-6. (PMID: 9443418)
Hum Reprod. 2021 Apr 20;36(5):1268-1278. (PMID: 33595055)
Gynecol Endocrinol. 2019 Jan;35(1):10-16. (PMID: 30044157)
Gynecol Oncol. 2022 Jan;164(1):195-201. (PMID: 34776242)
Am J Obstet Gynecol. 2004 Sep;191(3):733-40. (PMID: 15467532)
BMC Med Res Methodol. 2009 Jul 28;9:57. (PMID: 19638200)
Obstet Gynecol. 2016 May;127(5):828-836. (PMID: 27054934)
Cancer. 2009 Feb 1;115(3):531-9. (PMID: 19127543)
Hum Reprod Update. 2017 Jul 1;23(4):481-500. (PMID: 28498913)
Cancer Causes Control. 2008 Dec;19(10):1357-64. (PMID: 18704718)
Epidemiology. 2008 Mar;19(2):237-43. (PMID: 18223481)
Endocr Relat Cancer. 2013 Mar 22;20(2):251-62. (PMID: 23404857)
Gynecol Oncol. 2018 Dec;151(3):481-488. (PMID: 30322717)
Int J Cancer. 2017 Dec 15;141(12):2392-2399. (PMID: 28748634)
Epidemiology. 2020 May;31(3):402-408. (PMID: 32028322)
Eur J Epidemiol. 2018 Jan;33(1):5-14. (PMID: 29101596)
Am J Obstet Gynecol. 2003 Jul;189(1):280-94. (PMID: 12861175)
BMJ. 2016 Feb 25;352:i969. (PMID: 26916049)
Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):103-11. (PMID: 10667470)
Fertil Steril. 2000 Feb;73(2):205-11. (PMID: 10685516)
Arch Intern Med. 2004 Nov 8;164(20):2253-9. (PMID: 15534163)
Cancer Biol Med. 2017 Feb;14(1):9-32. (PMID: 28443200)
Hum Mol Genet. 2015 Oct 15;24(20):5955-64. (PMID: 26231222)
Ann Epidemiol. 2011 Mar;21(3):188-96. (PMID: 21109450)
J Natl Cancer Inst. 1998 Nov 4;90(21):1609-20. (PMID: 9811310)
Cancer Res. 2005 Jul 1;65(13):5974-81. (PMID: 15994977)
Lancet Oncol. 2012 Apr;13(4):385-94. (PMID: 22361336)
Biomedicines. 2021 Jan 08;9(1):. (PMID: 33435569)
Fertil Steril. 2001 Jul;76(1):1-10. (PMID: 11438312)
Fertil Steril. 2016 Jan;105(1):35-43.e1-10. (PMID: 26477498)
Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1738-41. (PMID: 16985038)
معلومات مُعتمدة: R01 CA087538 United States CA NCI NIH HHS; R01 CA058860 United States CA NCI NIH HHS; R01 CA080742 United States CA NCI NIH HHS; R01 CA074850 United States CA NCI NIH HHS; R01 CA063678 United States CA NCI NIH HHS; P50 CA105009 United States CA NCI NIH HHS; K07 CA080668 United States CA NCI NIH HHS; P30 CA008748 United States CA NCI NIH HHS; P30 CA014089 United States CA NCI NIH HHS; R03 CA115195 United States CA NCI NIH HHS; R01 CA054419 United States CA NCI NIH HHS; U19 CA148112 United States CA NCI NIH HHS; P01 CA017054 United States CA NCI NIH HHS; United Kingdom WT_ Wellcome Trust; R01 CA112523 United States CA NCI NIH HHS; R01 CA126841 United States CA NCI NIH HHS; N01 CN025403 United States CN NCI NIH HHS; N01 PC067010 United States PC NCI NIH HHS; P50 CA159981 United States CA NCI NIH HHS; M01 RR000056 United States RR NCRR NIH HHS; R01 CA095023 United States CA NCI NIH HHS; 076113 United Kingdom WT_ Wellcome Trust; R03 CA113148 United States CA NCI NIH HHS; R01 CA058598 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Endometriosis; effect modification; interactions; ovarian cancer; risk factors
المشرفين على المادة: 14807-96-6 (Talc)
0 (Estrogens)
تواريخ الأحداث: Date Created: 20221001 Date Completed: 20221025 Latest Revision: 20240615
رمز التحديث: 20240615
مُعرف محوري في PubMed: PMC9969849
DOI: 10.1016/j.fertnstert.2022.07.019
PMID: 36182623
قاعدة البيانات: MEDLINE
الوصف
تدمد:1556-5653
DOI:10.1016/j.fertnstert.2022.07.019